Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesExelixis Inc

Exelixis Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
69.57 USD 0.00(0%)
Last update at 2026-11-06T21:00:00Z
VOLUME
2003427
Market Cap
11918.03M
P/E
15.72

Momentum Score

…

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
68.01
Low
70.32
High
52 Week Price Range
33.76
Low
49.62
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Exelixis is a commercial-stage biotechnology company focused on developing and marketing oncology therapies, principally the tyrosine kinase inhibitor cabozantinib across multiple cancer indications, and maintaining a pipeline of oncology candidates. Long-term growth may be driven by expanded approvals, combination regimens with immunotherapies, international commercialization and pipeline progress. Investors may find it attractive because of a revenue-generating product franchise supporting continued R&D.
Key risks include heavy reliance on cabozantinib sales, competition from other targeted and immuno-oncology therapies, potential patent and pricing pressure, and clinical and regulatory execution risk.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
69.57
Dividend Yield
-
Revenue TTM
2320.13M
Revenue Per Share
8.54
Gross Profit TTM
2236.43M
Debt / Equity
0.08
ROE
35.53%
Net Debt
-309.45M
ROCE
36.60%
Diluted EPS TTM
2.92

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 941.21M 681.64M 257.52M 234.35M 294.15M
Net income 782.57M 521.27M 207.76M 182.28M 231.06M
Selling general administrative 467.03M 492.13M 542.71M 459.86M 401.71M
Selling and marketing expenses 51.70M - 40.00M - -
Gross profit 2236.43M 2092.49M 1757.66M 1553.15M 1382.10M
Reconciled depreciation 29.05M 28.80M 25.14M 20.88M 13.63M
Ebit 892.70M 689.95M 170.88M 180.61M 273.04M
Ebitda 921.76M 718.75M 196.60M 201.48M 286.67M
Depreciation and amortization 29.05M 28.80M 25.72M 20.88M 13.63M
Non operating income net other - - - -0.20M -0.18M
Operating income 872.19M 604.62M 170.88M 201.48M 286.67M
Other operating expenses 1447.93M 1564.08M 1659.32M 1409.58M 1148.30M
Interest expense - - - 53.74M 0.00M
Tax provision 158.64M 160.37M 30.98M 52.07M 63.09M
Interest income 69.21M 77.16M 82.14M 33.06M 7.67M
Net interest income 69.21M 77.16M 82.14M 33.06M 7.67M
Income tax expense 158.64M 160.37M 49.76M 52.07M 63.09M
Total revenue 2320.13M 2168.70M 1830.21M 1611.06M 1434.97M
Total operating expenses 1364.24M 1487.87M 1586.78M 1351.67M 1095.43M
Cost of revenue 83.70M 76.22M 72.55M 57.91M 52.87M
Total other income expense net 69.02M 77.02M 86.64M 32.87M 7.49M
Net income from continuing ops 782.57M 521.27M 92.07M 182.28M 231.06M
Net income applicable to common shares - - - 182.28M 231.06M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2844.42M 2947.69M 2942.36M 3071.49M 2616.24M
Other current assets 75.60M 68.48M 67.93M 62.21M 57.53M
Total liab 683.10M 703.49M 678.45M 583.06M 405.62M
Total stockholder equity 2161.32M 2244.20M 2263.91M 2488.43M 2210.61M
Other current liab 376.02M 365.58M 329.39M 285.11M 313.33M
Common stock 0.26M 0.28M 0.30M 0.32M 0.32M
Capital stock 0.26M 0.28M 0.30M 0.32M 0.32M
Retained earnings -76.83M -98.65M -173.35M -34.23M -216.51M
Other liab - - - 68.53M 16.76M
Good will 63.68M 63.68M 63.68M 63.68M 63.68M
Other assets - - - 286.88M 197.54M
Cash 482.49M 217.37M 262.99M 501.19M 647.17M
Total current liabilities 405.64M 403.77M 394.28M 324.36M 337.59M
Current deferred revenue - 2.74M 5.41M 6.58M 8.74M
Net debt -309.45M -26.55M -73.05M -311.02M -595.90M
Short term debt - 25.01M 25.71M - -8.74M
Short long term debt total 173.04M 190.82M 189.94M 190.17M 51.27M
Other stockholder equity 2234.41M 2343.91M 2440.71M 2536.85M 2427.56M
Property plant equipment - - - 110.62M 149.15M
Total current assets 1443.29M 1467.58M 1317.96M 1618.76M 1834.75M
Long term investments 603.60M 637.29M 728.72M 756.73M 371.11M
Net tangible assets - - - 2424.74M 2048.76M
Short term investments 576.60M 893.90M 732.31M 807.27M 819.90M
Net receivables 286.92M 265.44M 237.41M 214.78M 282.65M
Inventory 21.69M 22.39M 17.32M 33.30M 27.49M
Accounts payable 29.62M 38.19M 33.77M 32.67M 24.26M
Accumulated other comprehensive income 3.48M -1.35M -3.75M -14.52M -0.76M
Common stock total equity - - - 0.32M -
Retained earnings total equity - - - -34.23M -
Non currrent assets other 603.60M 27.87M - 290.58M 131.00M
Non current assets total 1401.13M 1480.11M 1624.40M 1452.73M 781.49M
Capital lease obligations 173.04M 190.82M 189.94M 190.17M 51.27M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 390.37M -116.78M -334.47M -385.96M 21.34M
Change to liabilities - - - -37.22M 66.10M
Total cashflows from investing activities 350.44M -116.78M - -524.41M -42.88M
Total cash from financing activities -969.59M -628.81M -546.05M 0.59M -14.80M
Change to operating activities - - - -91.32M 30.42M
Net income 782.57M 521.27M 207.76M 182.28M 231.06M
Change in cash 265.11M -45.62M -239.68M -161.21M 343.12M
Begin period cash flow 217.37M 262.99M 502.68M 663.89M 320.77M
End period cash flow 482.49M 217.37M 262.99M 502.68M 663.89M
Total cash from operating activities 884.27M 699.97M 333.32M 362.61M 400.80M
Depreciation 29.05M 28.80M 25.72M 20.88M 13.63M
Other cashflows from investing activities -61.75M -37.75M - -110.75M -10.00M
Change to inventory 12.22M 5.45M -12.98M -11.68M -13.21M
Change to account receivables -21.40M -27.95M -22.62M 66.85M -122.32M
Sale purchase of stock -947.51M -652.03M -579.50M 23.89M -39.11M
Other cashflows from financing activities -71.22M 23.23M 33.45M -47.19M 24.31M
Change to netincome - - - 153.94M 195.12M
Capital expenditures 39.93M 66.19M 162.97M 138.46M 64.22M
Change receivables - - - 66.85M -
Cash flows other operating - - - -12.43M -
Cash and cash equivalents changes - - - -161.21M -
Change in working capital -191.20M -13.45M -13.97M -12.80M -39.01M
Stock based compensation 112.98M 93.84M 106.34M 107.57M 119.82M
Other non cash items 24.62M 128.98M 140.68M 125.04M 28.77M
Free cash flow 844.34M 633.79M 170.35M 224.16M 336.58M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EXEL
Exelixis Inc		 -
-%		 69.57 15.72 14.01 5.14 5.13 4.39 11.06
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

1851 Harbor Bay Parkway, Alameda, CA, United States, 94502

650 837 7000

https://www.exelixis.com

1077

Name Title Year Born
Dr. Stelios Papadopoulos Ph.D. Co-Founder & Independent Chair of the Board 1948
Dr. Michael M. Morrissey Ph.D. CEO, Pres & Director 1961
Mr. Christopher J. Senner Exec. VP & CFO 1968
Dr. Peter Lamb Ph.D. Exec. VP of Scientific Strategy & Chief Scientific Officer 1961
Mr. Jeffrey J. Hessekiel J.D. Exec. VP, Gen. Counsel & Sec. 1969
Mr. Patrick J. Haley M.B.A., MBA Exec. VP of Commercial 1976
Dr. Dana T. Aftab Ph.D. Exec. VP of Bus. Operations NA
Ms. Susan T. Hubbard Exec. VP of Public Affairs & Investor Relations NA
Mr. Gregg Bernier VP of Marketing NA
Ms. Laura Dillard Exec. VP of HR NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…